Governance Viridian Therapeutics, Inc.

VRDN

US92790C1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:29:20 2026-06-11 pm EDT			5-day change	1st Jan Change
16.05 ^USD	+1.78%		-3.23%	-48.47%

Jun. 09	Viridian Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04:00 PM
May. 28	Viridian Therapeutics, Inc. Announces Voluntary Prepayment and Termination of Loan Agreement	CI

Executive Committee: Viridian Therapeutics, Inc.

Manager

Positions heldSince

Stephen Mahoney

55 year

Chief Executive Officer	2023-10-29
President	2023-10-29

Kirk Bertelsen

Chief Tech/Sci/R&D Officer

2023-12-31

Jennifer Tousignant

General Counsel

2024-02-14

Seth Harmon

46 year

Comptroller/Controller/Auditor	2023-09-11
Director of Finance/CFO	2023-09-11

Kyle Haraldsen

Chief Tech/Sci/R&D Officer

2023-12-31

Melissa Manno

Human Resources Officer

2023-12-31

Radhika Tripuraneni

46 year

Chief Tech/Sci/R&D Officer

2025-01-31

Thomas Beetham

57 year

Chief Operating Officer

2023-10-29

Diane Stroehmann

48 year

General Counsel

2023-12-31

Composition of the Board of Directors: Viridian Therapeutics, Inc.

Director

CommitteesSince

Tomas Kiselak

39 year

Compensation Committee	2023-06-21
Governance Committee	2021-05-31
Nominating Committee	2021-05-31
Compensation Committee Chair	2025-04-27

Christopher Cain

42 year

Compensation Committee	2025-04-27
Audit Committee	2025-03-09
Governance Committee Chair	2025-03-09
Nominating Committee Chair	2025-03-09
Governance Committee	2025-11-09
Nominating Committee	2025-11-09
Compensation Committee Chair	2025-11-09

Arlene Morris

74 year

Audit Committee	2024-05-06
Compensation Committee	2024-05-06
Governance Committee	2018-03-20
Nominating Committee	2018-03-20
Compensation Committee Chair	2019-07-25

Jeff Ajer

63 year

Audit Committee	2017-09-20
Compensation Committee	2017-09-20
Organization Committee	2017-09-20

Jennifer Moses

51 year

Compensation Committee	2021-07-13
Audit Committee Chair	2021-07-13

Stephen Mahoney

55 year

Director/Board Member

2023-10-29

Sarah Gheuens

47 year

Director/Board Member

2023-09-24

Latest Appointments: Viridian Therapeutics, Inc.

Mar. 30	4D Molecular Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2026	CI
Nov. 17	4D Molecular Therapeutics, Inc. Appoints Kristian Humer as Principal Financial Officer	CI
25-04-07	Viridian Therapeutics Appoints Jeff Ajer to Its Board of Directors	CI
25-03-10	Viridian Therapeutics, Inc. Announces Board and Committee Changes	CI
24-04-16	Foghorn Therapeutics Names Kristian Humer CFO	MT
24-02-16	Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	MT
24-02-16	Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	CI

More news

Former Officers and Directors: Viridian Therapeutics, Inc.

Insider

Positions held

SinceUntil

Peter Harwin

Director/Board Member	2020-10-27	2025-03-09
Independent Dir/Board Member	2020-10-27	2025-03-09

Thomas Ciulla

Chief Tech/Sci/R&D Officer	2024-01-07	2025-01-01
Corporate Officer/Principal	2022-12-31	2024-01-07

Barrett Katz

Chief Tech/Sci/R&D Officer

2021-01-17

2024-01-07

Angela Sheen

Chief Tech/Sci/R&D Officer	-	2024-01-01
Corporate Officer/Principal	2019-12-31	-

Helen Milton

General Counsel

2022-12-31

2024-01-01

Rob Henderson

Chief Tech/Sci/R&D Officer

2020-12-31

2023-12-31

Matthew Fearer

Public Communications Contact

2023-01-31

2023-11-30

Lara Meisner

General Counsel	2019-12-31	2023-10-31
Corporate Secretary	2019-12-31	2023-10-31

Janielle Newland

Chief Administrative Officer	-	2023-10-31
Human Resources Officer	2020-12-31	-

Scott Myers

Director/Board Member	2023-02-05	2023-10-31
Chief Executive Officer	2023-02-05	2023-10-31
President	2023-02-05	2023-10-31

Todd James

Investor Relations Contact	2021-12-31	2023-09-30
Corporate Officer/Principal	2021-12-31	2023-09-30

Kristian Humer

Comptroller/Controller/Auditor	2021-07-25	2023-09-11
Director of Finance/CFO	2021-07-25	2023-09-11

Carrie Melvin

Chief Operating Officer

2022-06-20

2023-04-10

Jonathan Violin

Director/Board Member	2021-01-14	2023-02-05
Chief Executive Officer	2021-01-14	2023-02-05
Chief Operating Officer	2020-10-27	2021-01-14
President	2020-10-27	2023-02-05

Deepa Rajagopalan

Corporate Officer/Principal

2021-06-30

2022-12-31

Jeffrey Hatfield

Director/Board Member	2017-03-31	2018-12-03
Chairman	2018-12-03	2021-05-31
Independent Dir/Board Member	2017-03-31	2021-05-31

Jason Leverone

Comptroller/Controller/Auditor	2017-02-12	2021-05-13
Director of Finance/CFO	2017-02-12	2021-05-13
Corporate Secretary	2017-02-12	2021-05-13
Treasurer	2017-02-12	2021-05-13

Lee Rauch

Director/Board Member	2020-09-12	2021-01-18
Chief Executive Officer	2020-09-12	2021-01-18
Chief Operating Officer	2020-06-17	2020-09-13
President	2020-09-12	2020-10-27

Diana M. Escolar

Chief Tech/Sci/R&D Officer

2017-12-31

2020-12-31

Vahe Bedian

Chief Tech/Sci/R&D Officer	2020-10-27	-
Corporate Officer/Principal	-	-

Kevin Koch

Director/Board Member	2017-02-12	2020-10-27
Independent Dir/Board Member	2017-02-12	2020-10-27

Thomas Hughes

Director/Board Member	2017-02-12	2020-10-27
Independent Dir/Board Member	2017-02-12	2020-10-27

Christopher Bowden

Director/Board Member	2017-08-09	2020-09-30
Independent Dir/Board Member	2017-08-09	2020-09-30

William Marshall

Director/Board Member	2017-02-12	2020-09-12
Chief Executive Officer	2017-02-12	2020-09-12
Founder	2017-02-12	2020-09-12
President	2017-02-12	2020-09-12

Paul Rubin

Chief Tech/Sci/R&D Officer

2017-02-12

2019-12-30

Adam Levy

Investor Relations Contact	2015-12-31	-
Corporate Officer/Principal	2015-12-31	2019-07-25

Bruce Booth

Chairman	2017-02-12	2018-12-03
Founder	2006-01-31	2018-12-03
Independent Dir/Board Member	2017-02-12	2018-12-03

John W. Creecy

Director/Board Member	2017-02-12	2017-08-09
Independent Dir/Board Member	2017-02-12	2017-08-09

Kyle Lefkoff

Director/Board Member	2017-02-12	2017-08-09
Independent Dir/Board Member	2017-02-12	2017-08-09
Director/Board Member	2006-12-31	2016-12-31

Samuel Riccitelli

Chief Executive Officer	2014-05-31	2017-02-12
President	2014-05-31	2017-02-12

Tamara Favorito

Director of Finance/CFO

2013-12-31

2017-02-12

Joseph Turner

Director/Board Member	2017-02-12	-
Independent Dir/Board Member	2017-02-12	-

Todd Brady

Director/Board Member

2015-09-30

2017-01-31

Chris H. Colecchi

Director/Board Member

Rusty Montgomery

Chief Tech/Sci/R&D Officer

Eric Newell Olson

Founder

Age distribution of managers

Parity Men Women

Male	13
Female	5

Of which Executive Committee

Male	6
Female	3

Of which Directors

Male	5
Female	2

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Employees

252

Sector

Biotechnology & Medical Research

More about the company